CONTENTS

• Rapid Reference 🚀
• Getting started
  • Types of drug reaction
  • Allergy history
  • How allergies cause harm
  • Basic science of beta-lactam allergy
• Techniques for allergy management
  • Skin testing
  • Graded challenge
  • Desensitization
• General approach to beta-lactam allergy in critical care
  • Groups of antibiotics with cross-allergy:
    • Aminopenicillins & select G1-G2 cephalosporins
    • Cefazolin
    • Nafcillin
    • Piperacillin-tazobactam
    • Cefepime & most G3 cephalosporins
    • Ceftazidime & aztreonam
    • Ceftaroline
    • Carbapenems
• Podcast
• Questions & discussion
• Pitfalls

---

rapid reference

(back to contents)

---

approach to patient with a beta-lactam allergy ✅

#1)  allergy history (more)

• Nature of reaction (severity, time delay to reaction, treatments required).
  • ⚠️ Beware of serious non-IgE reactions:  Steven-Johnson syndrome, acute interstitial nephritis, drug rash eosinophilia systemic symptoms (DRESS), hemolytic anemia.  In these situations, greater levels of caution are required.
  • Risk stratification:
    • Highest risk:  Definite anaphylaxis/angioedema.
    • Intermediate risk:  Urticaria.
    • Low risk:  Isolated rash or pruritus.
• Time elapsed since reactions.
• Antibiotics that the patient has been able to tolerate (review in EMR).

#2)  select an antibiotic that isn't cross-allergic

---

types of drug reaction

(back to contents)

---

Drug reactions vary greatly in severity and nature.  Below is a description of the most commonly encountered reactions.(30558872)  This chapter focuses on IgE-mediated allergic reactions.  However, patients rarely may develop severe non-IgE-mediated immune drug reactions (e.g. Steven Johnson Syndrome, acute interstitial nephritis).  Such patients should not be re-challenged with that drug or related agents.

Allergic drug reactions are traditionally classified into four types:

true allergic reaction (Type-I hypersensitivity, IgE-mediated)  

• Clinical presentation
  • Rapid onset (generally <1 hour, especially if IV administration; possibly up to six hours)
  • Mild form:  urticaria
  • More severe:  angioedema, anaphylaxis (hypotension, flushing, wheezing, nausea/vomiting, abdominal pain, stridor)
• Mechanism
  • IgE antibodies against drug cause mast cell degranulation
• Drugs that commonly cause this
  • Penicillins, cephalosporins
• Diagnosis
  • History, skin testing, drug challenge
• Treatment
  • Severe:  epinephrine, antihistamines, steroid.
  • Avoid drug and cross-allergic drugs in the future.
  • If use of the drug is essential, desensitization may be performed (more on this below).

anaphylactoid reaction

• Clinical presentation
  • Nearly identical to a true allergic reaction (above), albeit less tendency to cause shock.
  • Occurs during drug infusion or immediately after administration (never a delayed reaction).
• Mechanism
  • Drug directly stimulates mast cells, triggering the release of inflammatory mediators.
• Drugs that commonly cause this
  • Vancomycin (red person syndrome)
  • Fluoroquinolones
• Diagnosis
  • Clinical diagnosis based on scenario
• Treatment
  • Similar treatment to management of an allergic reaction, but these reactions are overall less severe and typically require only antihistamine.
  • Not a contraindication to using the drug in the future!  However, the drug should be administered more slowly.

cytopenias (class II hypersensitivity reaction)

• Clinical presentation
  • Hemolytic anemia or thrombocytopenia
  • Typically begins in under 3 days, but can be delayed up to two weeks.
• Mechanism
  • IgG and complement-mediated phagocytosis or cytotoxicity
• Drugs that commonly cause this
  • Penicillins, cephalosporins
  • Sulfonamides
  • Dapsone, rifampicin
• Treatment
  • Steroid and/or intravenous immunoglobulin
  • Avoid drug in the future, or agents from same class.

serum sickness like reaction (SSLR)(class III hypersensitivity reaction)

• Clinical presentation
  • Rare in adults.
  • Fever, rash, or arthralgia.
  • Nausea, vomiting, diarrhea may occur.
  • Typically, 1-3 weeks delayed after starting drug.
  • Unlike true serum sickness, renal and hepatic involvement is rare.(33292466)
• Mechanism
  • Creation of antibody-antigen complexes
• Drugs that commonly cause this
  • Penicillin, amoxicillin, cefaclor
  • Trimethoprim-sulfamethoxazole
• Diagnosis
  • Skin biopsy
• Treatment
  • Steroids in severe cases.
  • Generally a benign event and future courses of medication are unlikely to lead to recurrence.(33292466)

maculopapular rash (a.k.a. benign T-cell-mediated drug reaction)

• Clinical presentation
  • Diffuse maculopapular rash, may have associated eosinophilia.
  • Appears after days to weeks of therapy (typically ~2 weeks).
• Mechanism
  • Type IV cell-mediated reaction involving eosinophils
• Drugs that commonly cause this
  • Amoxicillin
  • Sulfonamide antibiotics
• Diagnosis
  • History and physical examination alone usually determine the diagnosis.
  • Skin biopsy, in severe or confusing cases.
• Treatment
  • Antihistamines or topical steroid (systemic steroid in severe cases).
  • Generally benign, can re-challenge with same drug depending on scenario.  In some cases, may even treat through this reaction, with careful monitoring for development of a more severe reaction.

acute interstitial nephritis (AIN)

• Clinical presentation
  • Acute kidney injury, sometimes with skin rash
  • Typically occurs between 3 days to a month after initiation of exposure
• Mechanism
  • Type IV hypersensitivity
• Drugs that commonly cause this
  • Semi-synthetic anti-staphylococcal penicillins (e.g. nafcillin, oxacillin)
  • Fluoroquinolones, rifampicin
• Diagnosis
  • Active urinary sediment (e.g. with leukocyte casts)
  • Peripheral blood eosinophilia may be seen
  • Renal biopsy is diagnostic
• Treatment
  • Steroid, possibly additional immunosuppressives
  • Avoid drug in the future, or agents from same class.

drug-induced liver injury (DILI)

• Clinical presentation
  • Hepatitis (often with substantially elevated bilirubin)
  • May have rash, fever, or eosinophilia
  • Occurs ~1-12 weeks after initiation of exposure
• Mechanism
  • T-cell immunity causes lysis of hepatocytes (Class IV hypersensitivity)
• Drugs that commonly cause this
  • Amoxicillin-clavulanate, flucoxacillin
  • Trimethoprim-sulfamethoxazole
  • Nitrofurantoin, minocycline, rifampicin
• Diagnosis
  • Laboratory evaluation for hepatitis (often diagnosis of exclusion)
  • Liver biopsy in severe cases
• Treatment
  • Steroid
  • Avoid drug in the future, or agents from same class.

drug reaction eosinophilia and systemic symptoms syndrome (DRESS)

• Clinical presentation
  • Begins 2-6 weeks after starting drug
  • Fever, rash
  • Peripheral eosinophilia
  • Lymphadenopathy or organ involvement (usually liver or kidney)
• Mechanism
  • T-cell mediated (Type-IV hypersensitivity)
• Drugs that commonly cause this
  • Vancomycin, all beta-lactam antibiotics
  • Sulphonamide antibiotics
• Treatment
  • Steroid in severe cases
  • Avoid drug in the future, or agents from same class.

Acute Generalized Exanthematous Pustulosis (AGEP)

• Clinical presentation
  • Begins within 48 hours of antibiotic exposure
  • Widespread pustular eruption with non-follicular sterile pustules
  • Fever, facial edema
  • 25% of patients have oral involvement
  • In severe cases can cause systemic inflammation with shock
• Mechanism
  • T-cell stimulated neutrophilic inflammation (Type IV hypersensitivity)
• Drugs that commonly cause this
  • Aminopenicillins, other beta-lactams
  • Clindamycin, vancomycin
  • Fluoroquinolones, Sulfonamides
• Diagnosis
  • History, physical diagnosis, skin biopsy.
  • Labs often show neutrophilia, mild eosinophilia.
  • After recovery, patch testing can help determine the causative agent.
• Treatment
  • Systemic steroid in severe cases.
  • Avoid drug in the future, or agents from same class.

Stevens-Johnson Syndrome (SJS) & Toxic Epidermal Necrolysis (TEN)

• Clinical presentation
  • Occurs 4 days to a month after antibiotic initiation.
  • Desquamating rash with mucosal involvement
  • SJS refers to more limited forms; TEN refers to patients with greater area of desquamated skin.
• Mechanism
  • CD8 T-cells stimulate keratinocyte death (Type IV hypersensitivity)
• Drugs that commonly cause this
  • Sulfonamide antimicrobials
  • Macrolides, fluoroquinolones
  • Cephalosporins are associated with an extremely low rate of severe cutaneous adverse reactions (e.g. Steven Johnson Syndrome).(28365277)
• Diagnosis
  • History, physical, skin biopsy
• Treatment
  • Aggressive supportive care in burn unit
  • Avoid drug in the future, or agents from same class.

---

allergy history

(back to contents)

---

questions to clarify a beta-lactam adverse reaction history (33292466)

• When did the reaction occur?
• Which medication was prescribed, and what was the route of administration?
• What was the indication for the medication?
• How many courses of this medication or a related medication have been administered?
• How many doses were received prior to onset of reaction?
• How soon after the most recent dose did the reaction occur?
• Were there any concurrent medications administered?
• What was the nature of the reaction?  Specifically ask about:
  • Raised, erythematous, pruritic rash with each lesion typically lasting <24 hours? (urticaria)
  • Swelling of the tongue, mouth, lips, or eyes?
  • Respiratory or hemodynamic changes?
  • Lesions or ulcers involving the mouth, lips, or eyes; skin desquamation.
  • Organ involvement such as hematologic, renal, or hepatic.
  • Joint pain (serum-sickness like reaction).
  • Rashes that were not hives, were mild, or delayed in onset. (mild type IV reaction)
• Was the medication stopped?
• Was medical attention sought?
• How was the reaction managed?
• How long did the symptoms last?
• Has the same medication been taken subsequently?  If so, was there a reaction?

A thoughtful allergy history is an essential step to determining a “pretest probability” regarding whether the patient has a clinically significant allergy.  Critical components are as follows:

nature of the reaction

• Signs & symptoms?
• Time delay from exposure to reaction?
  • An IgE-mediated allergic reaction should occur within minutes or a few hours.
• Treatments required to manage the drug reaction?
• Other drugs or illnesses present at the time of the reaction?
  • For example, mononucleosis treated with ampicillin often leads to a rash which isn't a true allergy.

timing & patterning of drug reaction.  

• Allergies resolve with time.  Over a decade, 80% of patients with a positive skin-test reaction to penicillin will become unreactive.(30644987)
  • A childhood history of “penicillin allergy” is less worrisome some decades later.
• Recurrent reactions which reproducibly occur in the near-past are most worrisome.

antibiotics that the patient has been able to tolerate

• Ask the patient (and/or interrogate the chart) to determine which antibiotic(s) the patient has been able to tolerate.
• If the patient has recently tolerated an antibiotic, this is powerful evidence that the same antibiotic (or a related agent) would be tolerated again.
  • Often patients are able to tolerate penicillins, but the “penicillin allergy” remains on the electronic medical record.

---

why allergies cause harm

(back to contents)

---

Over 30 million Americans carry a label of “penicillin allergy.”  Most of these patients (>95%) can actually tolerate penicillins.(30644987)  Concern regarding antibiotic allergy causes harm in roughly two ways:

 1) reduced antibiotic efficacy

• Beta-lactam antibiotics are often the most effective (e.g. nafcillin or cefazolin are more effective against methicillin-sensitive Staph aureus than vancomycin).
• Avoiding beta-lactam antibiotics leads to treatment with less effective antibiotics (e.g. vancomycin or clindamycin).

 2) increased antibiotic toxicity

• Avoidance of beta-lactam antibiotics promotes the use of unnecessarily broad-spectrum agents, which usually carry higher toxicity (e.g. selection of Clostridioides difficile or methicillin-resistant staph aureus).
• Classic examples of this phenomenon:
  • Septic patient with “penicillin allergy” is treated with a triple-antibiotic cocktail (e.g. vancomycin,  metronidazole, and aztreonam) instead of being treated with a single beta-lactam (e.g. piperacillin-tazobactam).
  • Patient with pneumonia and “penicillin allergy” is treated with a fluoroquinolone.

---

basic science & R1-chains

(back to contents)

---

good news:  IgE-mediated allergy to “beta-lactam antibiotics” doesn't exist

• Previously, it was believed that patients were allergic to the core beta-lactam ring structure.  An allergy to the core beta-lactam ring would be extremely problematic, because this would imply that the patient would be allergic to all beta-lactam antibiotics.
• Fortunately, allergic reactions to the core beta-lactam ring structure don't seem to exist.  Therefore, if a patient is allergic to one beta-lactam, this doesn't mean that they will necessarily be allergic to all drugs in this class.

IgE-mediated allergies occur to R1-side chains 

• Patients are actually allergic to the R1-side chain of individual beta-lactam antibiotics.
  • Beta-lactams are too small to bind to IgE.  In order to be recognized by the immune system, they must stick to proteins.
  • When a beta-lactam is attached to a protein, the R1-side chain sticks out.  It plays a key role in binding to antibodies, and thereby driving allergic reactions.
• This can be a bit confusing:
  • Allergy to certain antibiotics will cross-react with antibiotics which have similar R1-side chain (e.g. ampicillin is cross-allergic with some first-generation cephalosporins).
  • Some antibiotics have side-chains which are unique and not cross-allergic with other drugs (e.g. cefazolin and ceftaroline).

The key to determining cross-allergy is structural similarity between R1-side chains (not necessarily how a specific antibiotic is classified).  For example, aztreonam and ceftazidime have identical R1 side-chains and are cross-allergic (despite belonging to different classes of beta-lactams):

The R1-side chains of many beta-lactams are shown below.  This provides a background for understanding the cross-reactivity of various beta-lactams.

“penicillin allergy” doesn't exist!

• The term “penicillins” refers to four general groups of antibiotics, as shown below.
• “Penicillin allergy” is a misleading and sloppy term for a few reasons:
  • All penicillins are not cross allergic (e.g. piperacillin doesn't seem to be cross-allergic with penicillin-G).
  • Some penicillins are cross-allergic with non-penicillins (e.g. amoxicillin and some first-generation cephalosporins).
• When people say “penicillin allergy” they are most commonly referring to aminopenicillin allergy (allergy to ampicillin, penicillin G, penicillin VK, and early-generation cephalosporins including cefaclor, cephalexin, cephradine, cephaloglycin)
  • Honestly, even “aminopenicillin allergy” may be an excessively broad term, because ampicillin and amoxicillin may not be cross-allergic.  So, it's possible that there are actually two distinct types of aminopenicillin allergy.
• “Cephalosporin allergy” also doesn't exist.

---

penicillin skin testing

(back to contents)

---

benefits of skin testing

• Skin testing is sensitive for an allergy (absence of a skin response carries 97-99% predictive value that penicillin can be tolerated).
• Institution-wide initiatives involving broad use of skin testing can improve antibiotic stewardship.
  • Negative skin test result refutes a “penicillin allergy,” allowing this label to be removed without causing further confusion.

drawbacks of skin testing

• Skin tests are clinically validated only for penicillin allergy (not for other antibiotics).
  • A negative penicillin allergy doesn't exclude allergies to structurally unrelated beta-lactams (e.g., aminopenicillins, cephalosporins, or piperacillin).(17620077)
• Necessary materials are unavailable at many hospitals.
• Skin testing causes a time delay and requires trained staff (who may not be available during off hours).
• Specificity of a positive result is unclear (because patients who test positive aren't challenged with penicillin).
  • Among patients with a positive result, as many as 50% may actually be able to tolerate penicillin! (29304914)

bottom line?

• Skin testing isn't a logistically viable solution for critically ill patients with acute infection.
• Penicillin skin testing is increasingly irrelevant, as we begin to realize that natural penicillins are actually cross-allergic with very few antibiotics (i.e. “penicillin allergy” doesn't exist).
  • For example, preoperative skin testing has been touted as a way to allow patients to receive cefazolin for perioperative prophylaxis.(28965632)  But cefazolin isn't cross-allergic with penicillin!  So you don't need a skin test – you can just give cefazolin (more on this below).

---

graded challenge

(back to contents)

---

general concept

• Used in situations where an anaphylactic reaction is possible, but seems less likely.
• The patient is first exposed to a small dose of the drug and, if this is tolerated, escalating doses are administered.
• Unlike penicillin skin testing, this can be performed with any intravenous antibiotic.
• ED or ICU admission represents an opportunity to perform a graded challenge, since the patient is being intensely monitored.
  • An intubated patient is theoretically the safest context for performing graded challenge, because the patient already has a secured airway.  It's not worth intubating a patient solely to perform the graded challenge, but if the patient is intubated for another reason this may enhance safety.

how to perform a graded challenge

• No consensus exists about exactly how to accomplish this.
• One common approach is as follows:  infuse 10% of the dose slowly over ~60 minutes, with close observation.  If this is tolerated, the remainder of the dose is given at the usual rate.(30644987; 31749148)
  • This is easy to do with any antibiotic infused via a mini-bag (as most antibiotics are, in critical illness).   You're essentially starting the antibiotic at a very low infusion rate and carefully watching the patient.  If nothing happens after an hour, then increase the infusion to a normal rate.
  • This costs nothing (no additional materials are required).
  • The only drawback is that this will delay administration of antibiotic by about an hour.

---

desensitization

(back to contents)

---

what is desensitization?

• Patient with a known allergy (or highly suspected allergy) is gradually exposed to escalating doses of drug.
• An allergic reaction occurs and is managed medically.  After controlling the allergic reaction, more drug is given!
  • Desensitization:  Intentionally provoke an allergic reaction and treat through it.
  • Graded challenge:  Test for allergic reaction and stop drug administration if a reaction occurs.
• Eventually IgE antibodies against the drug are depleted and the reaction subsides.  Now the patient is able to tolerate the drug.
  • However, the drug must be continually administered to the patient in order for desensitization to work.  If the patient stops being exposed for a long period of time, re-exposure may cause anaphylaxis.

how to perform desensitization

• Rigorous, validated protocols must be followed carefully.
• Initially a very tiny antibiotic dose is administered, and this is gradually increased over time (e.g. over a period of 6-12 hours).
• If allergic reactions occur, antibiotic administration is temporary held and the reaction is treated.  Once the reaction subsides, additional antibiotic is administered.
• Must be performed only in an ICU or ED with the capacity to immediately treat anaphylaxis or angioedema.

role of desensitization

• Occasionally used in situations where a specific antibiotic is uniquely useful.
• With increasing understanding about the lack of cross-reactivity between most antibiotics, this is rarely required currently.

---

general approach to beta-lactam allergy in critical care

(back to contents)

---

For most patients presenting to critical care with an acute infection, logistics don't allow for sophisticated approaches such as skin testing or desensitization.  Fortunately, we can generally select safe and effective antibiotics simply based on understanding which antibiotics are truly cross-allergic with each other.

As discussed above, the degree of cross-reaction is far lower than has previously been believed.  For example, there's no such thing as a “penicillin allergy” to all penicillins.  By breaking down cross-allergic medications into smaller groups, we can generally manage to find an adequate antibiotic which is not cross-allergic with medications that the patient is allergic to.(30558872, 28965632)

Overall, the incidence of anaphylaxis due to cephalosporins is about ten times lower than for penicillins.(28965632, 30916014)  This may reflect that the molecular structure of cephalosporins is less likely to break apart and stick to proteins (a step involved in IgE-mediated allergic reactions due to penicillins).  However, different medications vary considerably in their likelihood of eliciting allergic reactions.

It's important to realize that the risk of an anaphylactic reaction is never zero, for any patient or with any medication.  Patients with a history of anaphylaxis to one medication may be more likely to develop anaphylaxis to other medications in general.  As is often the case in medicine, our task is to minimize risk as much as possible – but we can never get to zero risk.  In fact, attempting to achieve zero risk could merely lead to more harms (e.g., placing the patient on a regimen of vancomycin, aztreonam, and levofloxacin – which likely increases their overall risk of being harmed by a medication side-effect!).

Two cross-reactivity matrices are shown above.  The most efficient way to operationalize this data may be to break drugs into eight groups of cross-allergic antibiotics, listed below.  Data is continuing to emerge on this topic.  Over time, we will likely learn that these groups may be overly inclusive (i.e., some may be broken down into smaller groups).

---

aminopenicillins and select G1-G2 cephalosporins

(back to contents)

---

medications in this group:

• Ampicillin, Amoxicillin.
• Some G1 cephalosporins, e.g.:
  • Cefadroxil.
  • Cephalexin.
• Some G2 cephalosporins, e.g.:
  • Cefaclor.
  • Cefprozil.

comments:

• Although aminopenicillin allergy is often equated with “penicillin allergy,” penicillin G itself may not truly belong within this group.(28483315, 33500632)  Specifically, there are many patients who are allergic to aminopenicillins, but not Penicillin G.(31826341)  

---

cefazolin

(back to contents)

---

medications in this group:

• Cefazolin.
• Ceftezole (not available in the United States)

comments:

• Cefazolin has a unique R-side chain that is not cross-allergic with other beta-lactams available in the United States.(30916014)  
• Cefazolin is safe in patients with penicillin allergy (or at least as safe as any other antibiotic; patients with a penicillin allergy are more likely to be allergic to any antibiotic).(31362351)

---

nafcillin

(back to contents)

---

medications in this group:

• Nafcillin.

comments:

• Nafcillin seems to be a uniquely non-allergic medication.  There are hardly any reports of anaphylaxis against it at all (perhaps only one).(6465179)
• Structurally, the R1 side-chain of nafcillin is rather unique, and unlike other beta-lactams.  Nafcillin does not appear to be cross-allergic with penicillin G or aminopenicillins.
• It remains unclear whether nafcillin may be cross-allergic with other semisynthetic penicillins (e.g., oxacillin, flucloxacillin).

---

piperacillin-tazobactam

(back to contents)

---

medications in this group:

• Piperacillin-Tazobactam.

comments:

• The structure of piperacillin-tazobactam is quite distinct from aminopenicillins or cephalosporins (figure below).  This predicts a lack of cross-allergy.  About 15% of patients with verified allergies to piperacillin-tazobactam are also allergic to penicillin, likely due to the coexistence of multiple independent drug allergies.  Most patients with penicillin allergy can likely tolerate piperacillin-tazobactam.(33444815, 33474862, 32320796). 
• ⚠️ It is unclear whether tazobactam could be cross-allergic with sulbactam or clavulanate.  Caution should be exercised for patients with a history of severe allergy to ampicillin-sulbactam or amoxicillin-clavulanate.(31261671, 33444815)

---

cefepime and most G3 cephalosporins

(back to contents)

---

medications in this group:

• Most G3 cephalosporins except ceftazidime, for example:
  • Ceftriaxone.
  • Cefotaxime.
  • Cefpodoxime.
• G4 cephalosporins:  Cefepime.

comments:

• It is increasingly recognized that different groups of cephalosporins are not cross-allergic.(25930196)

---

ceftazidime and aztreonam

(back to contents)

---

medications in this group:

• Ceftazidime (a G3 cephalosporin).
• Aztreonam.
• Cefiderocol (a G5 cephalosporin).

comments:

• Ceftazidime and aztreonam have the same R1 side chain (figure below).  This makes them cross-allergic, even though they are in different sub-classes of beta-lactam antibiotics.
• Aztreonam has historically been regarded as safe in “beta-lactam allergy,” but it is actually cross-reactive with ceftazidime.  Nonetheless, aztreonam does have a proud track record of being safely employed in patients with allergy to a variety of other beta-lactam antibiotics.
• Ceftazidime might be an option for some patients unable to tolerate cefepime or other G3 cephalosporins.(11167362, 31479769)

---

ceftaroline

(back to contents)

---

medications in this group:

• Ceftaroline (G5 cephalosporin).

comments:

• To date there aren't many reports of anaphylaxis from ceftaroline.  However, a recent retrospective case series suggested that ceftaroline may cause unusually high rates of T-cell mediated hypersensitivity reactions (e.g., cytopenias, hepatitis, nephritis, desquamating skin rash).(27130709)

---

carbapenems

(back to contents)

---

medications in this group:

• Ertapenem.
• Meropenem.

comments:

• Meropenem seems nearly incapable of eliciting anaphylactic reactions.
  • Structurally, meropenem has a stubby and nearly nonexistent R1 side-chain (image below).  This explains why it doesn't cause allergy.
  • Evidence supports the use of meropenem in patients with a history of anaphylaxis to aminopenicillins.(17696578, 25048853, 18467251, 25566799)
  • Meropenem can be a safe option for broad-spectrum coverage in patients with a myriad of antibiotic allergies.
• Imipenem-cilastatin may cross-react with some beta-lactam antibiotics, most likely due to the cilastatin component.

---

podcast

(back to contents)

---

Follow us on iTunes

---

questions & discussion

(back to contents)

---

To keep this page small and fast, questions & discussion about this post can be found on another page here.

• Being misled by the terms “penicillin allergy” and “cephalosporin allergy,” which should be eliminated.
• Failure to obtain a thorough allergy history that documents the exact nature of the drug reaction.
• Failure to realize that for patients with allergy to one beta-lactam, a non-cross-allergic beta-lactam can usually be used safely.
• Under-utilization of graded challenge to disprove allergic reactions.  The best time to perform a graded challenge is when the patient is being intensively monitored in an ICU or ED.

Guide to emoji hyperlinks 

•  = Link to online calculator.
•  = Link to Medscape monograph about a drug.
•  = Link to IBCC section about a drug.
•  = Link to IBCC section covering that topic.
•  = Link to FOAMed site with related information.
•  = Link to supplemental media.

Going further

• Meropenem safe in PCN allergy (PulmCrit)
• Cephalosporins in PCN allergy
  • Mythbuster: 10% cephalosporin-penicillin cross-reactivity (Bryan Hayes, ALIEM)
  • Cephalosporins and penicillin cross-reactivity (Rebel EM)
  • Cephalosporins can be used in PCN allergy (EM Literature of Note)
• Is piperacillin-tazobactam safe in penicillin allergy?  (PulmCrit)
• Low utility of fluoroquinolones in critical care   (PulmCrit)
• Ranking antibiotics in order of allergenicity (PulmCrit)